CoChat

A randomised trial of anti-GM-CSF otilimab in severe COVID-19 pneumonia (OSCAR)

Open access
Patel, Jatin, Bass, Damon, Beishuizen, Albertus, Bocca Ruiz, Xavier, Boughanmi, Hatem, Cahn, Anthony, Colombo, Hugo, Criner, Gerard J., Davy, Katherine, de-Miguel-Díez, Javier, Doreski, Pablo A., Fernandes, Sofia, François, Bruno, Gupta, Anubha, Hanrott, Kate, Hatlen, Timothy, Inman, Dave, Isaacs, John D., Jarvis, Emily, Kostina, Natalia, Kropotina, Tatiana, Lacherade, Jean-Claude, Lakshminarayanan, Divya, Martinez-Ayala, Pedro, McEvoy, Charlene, Meziani, Ferhat, Monchi, Mehran, Mukherjee, Sumanta, Muñoz-Bermúdez, Rosana, Neisen, Jessica, O'Shea, Ciara, Plantefeve, Gaëtan, Schifano, Lorrie, Schwab, Lee E., Shahid, Zainab, Shirano, Michinori, Smith, Julia E., Sprinz, Eduardo, Summers, Charlotte, Terzi, Nicolas, Tidswell, Mark A., Trefilova, Yuliya, Williamson, Russell, Wyncoll, Duncan, Layton, Mark · 2023 · European Respiratory Journal
Cited by 59

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Abstract

Background: Granulocyte–macrophage colony-stimulating factor (GM-CSF) and dysregulated myeloid cell responses are implicated in the pathophysiology and severity of COVID-19. Methods: In this randomised, sequential, multicentre, placebo-controlled, double-blind study, adults aged 18–79 years (Part 1) or ≥70 years (Part 2) with severe COVID-19, respiratory failure and systemic inflammation (elevated C-reactive protein/ferritin) received a single intravenous infusion of otilimab 90 mg (human anti-GM-CSF monoclonal antibody) plus standard care ( NCT04376684 ). The primary outcome was the proportion of patients alive and free of respiratory failure at Day 28. Results: In Part 1 (n=806 randomised 1:1 otilimab:placebo), 71% of otilimab-treated patients were alive and free of respiratory failure at Day 28 versus 67% who received placebo; the model-adjusted difference of 5.3% was not statistically significant (95% CI −0.8–11.4%, p=0.09). A nominally significant model-adjusted difference of 19.1% (95% CI 5.2–33.1%, p=0.009) was observed in the predefined 70–79 years subgroup, but this was not confirmed in Part 2 (n=350 randomised) where the model-adjusted difference was 0.9% (95% CI −9.3–11.2%, p=0.86). Compared with placebo, otilimab resulted in lower serum concentrations of key inflammatory markers, including the putative pharmacodynamic biomarker CC chemokine ligand 17, indicative of GM-CSF pathway blockade. Adverse events were comparable between groups and consistent with severe COVID-19. Conclusions: There was no significant difference in the proportion of patients alive and free of respiratory failure at Day 28. However, despite the lack of clinical benefit, a reduction in inflammatory markers was observed with otilimab, in addition to an acceptable safety profile.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1183/13993003.01870-2021

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 18 references

Cited by

See all 59

Metadata

Authors
Patel, J., Bass, D., Beishuizen, A., Bocca Ruiz, X., Boughanmi, H., Cahn, A., Colombo, H., Criner, G. J., Davy, K., de-Miguel-Díez, J., Doreski, P. A., Fernandes, S., François, B., Gupta, A., Hanrott, K., Hatlen, T., Inman, D., Isaacs, J. D., Jarvis, E., Kostina, N., Kropotina, T., Lacherade, J.-C., Lakshminarayanan, D., Martinez-Ayala, P., McEvoy, C., Meziani, F., Monchi, M., Mukherjee, S., Muñoz-Bermúdez, R., Neisen, J., O'Shea, C., Plantefeve, G., Schifano, L., Schwab, L. E., Shahid, Z., Shirano, M., Smith, J. E., Sprinz, E., Summers, C., Terzi, N., Tidswell, M. A., Trefilova, Y., Williamson, R., Wyncoll, D., & Layton, M.
Venue
European Respiratory Journal
Published
2022-10-13
Volume
61
Issue
2
Pages
2101870
ISSN
  • 0903-1936 (ISSN-L)
  • 1399-3003
OpenAlex
W4304957329
Cited by
59
References
18
FWCI
5.44
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A randomised trial of anti-GM-CSF otilimab in severe COVID-19 pneumonia (OSCAR). https://app.cochat.ai/papers/10.1183/13993003.01870-2021
The paper
Patel, J., Bass, D., Beishuizen, A., Bocca Ruiz, X., Boughanmi, H., Cahn, A., Colombo, H., Criner, G. J., Davy, K., de-Miguel-Díez, J., Doreski, P. A., Fernandes, S., François, B., Gupta, A., Hanrott, K., Hatlen, T., Inman, D., Isaacs, J. D., Jarvis, E., . . . Layton, M. (2023). A randomised trial of anti-GM-CSF otilimab in severe COVID-19 pneumonia (OSCAR). European Respiratory Journal. https://doi.org/10.1183/13993003.01870-2021

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.